I'll research Albemarle (ALB) before writing the preview. Let me start by gathering recent filings, earnings, and news.Let me dig into the most recent earnings materials and price action.The stock has fallen sharply from its April peak (~$215) to ~$120 despite strong Q1 results. Let me investigate the recent drivers and lithium market context.Let me get context on the recent lithium market and the sharp stock decline into late July.Let me compute some precise stock statistics for the preview.# Albemarle (ALB) — Q2 2026 Earnings Preview
The central tension going into this print is the disconnect between Albemarle's rapidly improving financials and a stock that has been cut nearly in half from its spring highs.
Bottom line: This is a "prove the durability of the recovery" quarter. With the stock this washed out, the risk/reward hinges less on the Q2 headline beat and more on whether lithium pricing commentary and the full-year scenario framework hold up.
Q1 set a high bar and reframed the story from survival to recovery:
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Net sales | $1.43B | $1.08B | +33% |
| Adj. EBITDA | $664M | $267M | +148% |
| Adj. EBITDA margin | 46.5% | 24.8% | +21.7pp |
| GAAP EPS | $2.34 | ~$0.00 | NM |
| Adjusted EPS | $2.95 | $(0.18) | NM |
| Free cash flow | $248M | — | — |
ALB doesn't guide to a point estimate; it gives market-price scenarios. The full-year framework:
| Avg. lithium price | ~$10/kg (2025 avg) | ~$20/kg (Q1'26 avg) | ~$30/kg (2021–25 avg) |
|---|---|---|---|
| Total net sales | $4.1–4.3B | $5.7–6.0B | $7.5–7.8B |
| Total adj. EBITDA | $0.9–1.0B | $2.4–2.6B | $4.2–4.4B |
Scenarios assume flat pricing flowing through the contract book (~40% of volume on long-term agreements, ~60% spot) and spodumene at ~10% of the LCE price. Key nuance: at the Q1 call (early May), Chinese spot was ~$27/kg, and management conceded that if it held, there was upside to the $20 scenario. The subsequent stock decline suggests the market is skeptical prices held. Listen for: where Q2 realized/market price landed, and whether they nudge toward the $30 scenario or stay conservative.
Management pre-warned that Q2 Energy Storage sales and EBITDA rise sequentially (contract lag catches up to higher spot), but margin compresses sequentially due to (i) higher-cost spodumene inventory flowing through COGS and (ii) Middle East–related cost inflation. Don't read a lower sequential margin as deterioration — it's timing.
The macro backdrop has shifted materially: a US/Israel–Iran conflict has pushed oil above $100 and effectively closed the Strait of Hormuz for stretches (evident in refiner windfalls at Marathon, Chevron, Diamondback this quarter). - Headwind: ALB flagged an unmitigated $70–90M full-year cost impact (sulfuric acid, logistics/supply chain). Its Jordan Bromine Company (JBC) JV sits in the region (and separately recovered from a Dec-2025 flood). - Offsets/tailwinds: lower interest expense, stronger Specialties (bromine price/volume), and a potential energy-security tailwind for stationary storage. Watch whether the $70–90M estimate is revised and whether it's still fully offset.
Q1 raised FY Specialties to $1.3–1.5B sales / $225–275M EBITDA (high-teens margin). But management was cautious on the back half — Chinese bromine spot has eased as seasonal supply returned, and petrochemicals/oil-and-gas end markets are volatile. Q2 EBITDA was guided "up modestly." Watch for confidence (or hedging) on H2.
FY Energy Storage sales volumes are guided ~flat (production up, but 2025 inventory drawdowns create tough H2 comps). Q1's 53kt was the easy comp; H2 comps get harder. Any signal that resource ramps (Greenbushes CGP3, Wodgina 3-train run-rate) are outperforming could unlock volume upside.
Bullish triggers: - Confirmation that Q2 lithium realized price tracked toward/above the $20 scenario, with constructive commentary on ESS demand (battery-maker order books were described as full through early 2027). - A Specialties H2 confidence bump and/or the Middle East cost hit trending to the low end. - Any progress/de-escalation on the Greenbushes JV dispute or favorable contract-renewal signals.
Bearish triggers: - Evidence lithium prices rolled over in June/July (consistent with the stock), pushing the narrative toward the $10–$20 scenario band. - Escalating Greenbushes partner conflict or safety/production disruption. - Middle East cost creep beyond $90M, or a Specialties H2 walk-down.
Albemarle enters the print with a de-risked balance sheet, strong Q1 momentum, and a deeply discounted stock — but the market is clearly pricing in doubt about lithium price durability and demand elasticity at higher prices. The report is less about the near-certain YoY EBITDA surge and more about management's read on lithium pricing, the sustainability of the Specialties raise, quantification of the Middle East impact, and the Greenbushes/contract-renewal overhangs. Given the ~44% drawdown from the April peak, expectations are low, which skews the setup asymmetrically to the upside if pricing commentary holds — and leaves little cushion if it disappoints.
Note: Figures are drawn from Albemarle's Q1 2026 earnings release and call, recent press/market news, and daily price data through Aug 4, 2026. All forward figures are company "scenario" considerations, not point guidance.